# 1. Financial Performance ## A. Key Figures * Q2 Revenue: ₹16,585 Mn (~₹165.85 Cr) consolidated (+25.2% INR, +20% CC) · Q2 Adjusted EBITDA: ₹4,352 Mn (+25.6%) * H1 Revenue: ₹31,974 Mn (~₹319.74 Cr) (+25.5% INR, +21.4% CC) · H1 Adjusted EBITDA: ₹8,039 Mn (+26%) * **Q2 Adjusted PAT:** **₹3,010 Mn** (+84%) · **H1 Adjusted PAT:** **₹5,007 Mn** (+62.4%) * **ROCE:** **>50%** (stable) · **DSOs:** **78 days** * H1 OCF (underlying): 74% cash conversion · FCF: ₹4,776 million ## B. Revenue Growth * **Strong Constant Currency Momentum:** Revenue growth accelerated in Q2 to 20% in constant currency, reflecting robust demand and effective market positioning in payer and provider segments. * **Organic Expansion Sustained:** H1 organic growth of 9% in INR terms underscores continued traction from core operations, net of all cannibalization from tech and delivery shifts. * **Technology-Enabled B2B Model:** Growth in national payer offerings driven by integrated tech-and-services "stitched" solutions, signaling scalable client value. ## C. Profitability Trends * **Disproportionate PAT Growth:** Adjusted PAT surged 84% YoY in Q2, significantly outpacing EBITDA growth due to lower finance costs, favorable forex, and high operating leverage. * **Adjusted Metrics Reflect Core Strength:** Adjusted EBITDA excludes earn-out expenses, share-based payments (non-cash, no dilution), and FX gains, highlighting strong underlying delivery efficiency and GenAI-driven optimization. * **Acquisition Accounting Impact:** Earn-out provisions for Payment Integrity, BirchAI, and BroadPath are expensed over time; key earn-outs set to conclude by FY-end with full recognition of share-based awards by FY '29. ## D. Balance Sheet Health * **Capital Efficiency Intact:** ROCE remains above 50%, supported by disciplined capital allocation, site consolidations, and minimal fixed asset additions. * **Debt Reduction Pathway Clear:** All external borrowings, including a parent rupee loan at 8%, targeted for full repayment by end of next fiscal, in line with RBI norms. ## E. Cash Flow Generation * **Underlying Cash Strength Robust:** Despite a reported OCF decline due to $19M advanced tax payments and $6M unrealized gains, underlying H1 cash conversion was 74%, with **₹6 Cr free cash flow** generated. * **Dividend Policy Active:** Interim dividend of ₹0.05 per share approved for Q3, reflecting confidence in cash flow resilience despite no formal payout ratio. * **Amortization Runoff Visible:** $5M annual amortization of U.S. customer intangibles (16-year life) provides visibility into future non-cash charges. --- # 2. Client & Contract Metrics ## A. Key Figures * Annual Contract Value (ACV): $34 Mn total new and existing clients * **Client Count:** **82 active clients** as of Sep 30, 2025 (+5 new, 24 expansions) * **Quarterly Revenue Run Rate:** **~$190 Mn** (distinct from ACV) * **Employee Base:** **44,185** across five countries * Attrition Rate: 26.3% annualized, stable YoY ## B. Client Growth & Retention * **Strong Client Momentum:** Robust deal flow with **5 new client additions** and **24 existing client expansions**, reflecting deepening partnerships amid macro uncertainty. * **Backbone of Growth:** Revenue expansion primarily driven by **scope broadening within existing clients**, while new clients contribute incrementally over time. * **Stable Delivery Model:** Low attrition and scalable talent base support consistent service delivery and operational maturity. ## C. Deal Design & Pricing Strategy * **End-to-End Value Capture:** Deal structuring includes **upstream process integration**, enabling wallet share gains by displacing other providers through comprehensive solutions. * **Innovative Pricing Models:** Increasing adoption of **PMPM (per-member-per-month)** pricing with **gain-share mechanisms**, aligning incentives and capturing value from cost savings. * **GenAI-Driven Revenue:** **AI-handled transactions billed at significantly lower rates** than human-performed work, enabling transparent attribution of **revenue linked to generative AI** adoption. * **Cost Control & Currency Leverage:** No COLA clauses in offshore contracts; company relies on **internal efficiencies and selective currency leverage** to offset inflation, maintaining margin stability. * **Client Appetite for Scale:** Larger deals being negotiated in exchange for **committed 20–30% cost reductions**, accelerating full outsourcing of internal client processes. --- # 3. Segment & Vertical Performance ## A. Key Figures * Payer Business Growth: 24.2% YoY (+88.5% revenue mix) * Provider Business Growth: 33.4% YoY (11.5% revenue mix) ## B. Payer Business Trends * **Strategic Expansion:** Payer segment shows **strong momentum** with cross-sell wins, including a new SOW from a large national Payer and a mid-sized health plan, signaling expanded footprint. * **Differentiated Solutions:** Secured engagement with a large national Payer seeking next-gen savings, leveraging **end-to-end value chain expertise** beyond claims processing. ## C. Provider Business Trends * **Service Line Evolution:** Provider offerings expanding into **provider payments and engagement**, responding to regulatory-driven demand for tighter eligibility and revenue cycle management. ## D. BroadPath Integration * **Cross-Sell Acceleration:** Multiple proposals submitted to BroadPath clients in H1 FY26, targeting **larger, transformation-led, end-to-end service models**. --- # 4. AI & Technology Levers ## A. Key Figures * **AI Use Cases Deployed:** **25** across nine clients (up from 18 last quarter) * **Cost Savings Range:** **20%–40%** committed or achieved in client engagements * **AI Agent Cost Efficiency:** **25–35%** of offshore human agent cost · **10–12%** of onshore human agent cost * **Automation Potential:** **20–25%** of transactions fully automatable · **15–20%** productivity gain in remaining human-led processes ## B. GenAI Use Cases * **Consulting-Led AI Integration:** GenAI embedded in deal constructs and delivery frameworks, driving large-scale efficiency and value creation for existing clients. * **Dual-Use AI Strategy:** AI applied to both client solutions and internal workforce upskilling via Agentic AI platforms, enhancing retention and transformation readiness. * **Commercialization Momentum:** 25 deployed use cases across nine clients reflect accelerating adoption, with case studies illustrating scalable, integrated AI solutions. * **Revenue Trade-offs Acknowledged:** Management expects some revenue cannibalization from committed savings but views AI expansion as a net growth driver through scope broadening. ## C. Automation Savings * **Transformation-in-Place Model:** Combines process reengineering with GenAI to unlock incremental **20% cost savings**, particularly in mature client environments. * **Higher Savings in Immature Clients:** Regional or less mature clients offer greater savings potential (**25–40%**) due to untapped efficiency opportunities. * **Hybrid Workflows Limit Attribution:** Financial impact of GenAI is difficult to isolate, as most workflows remain human-AI hybrids, though full automation enables direct revenue attribution. * **Operational Leverage:** AI-driven productivity serves as a key margin protection lever alongside currency benefits, with claims and network management seeing highest disruption potential. ## D. Productivity Impact * **Technology-Enabled Expansion:** Strengthened AI capabilities support deeper client engagement and entry into the midmarket segment. --- # 5. Demand & Seasonality ## A. Key Figures * **H2 Revenue Share:** **53–54%** of annual revenue (historical trend) ## B. Open Enrollment Cycle * **Seasonal Inflection Point:** The annual enrollment period (AEP) for H2 FY26 has commenced, marking the start of a critical demand cycle for Payer clients, with operations scaled accordingly. * **Q3 Revenue Peak:** Q3 is expected to deliver both year-on-year and sequential growth, driven by open enrollments and BroadPath’s contribution to member acquisition. * **Heightened Seasonality:** BroadPath’s acquisition has increased overall revenue concentration in H2, with Q3 now expected to be the largest revenue quarter for Sagility versus prior years. ## C. H2 Revenue Strength * **Divergent Q4 Trends:** While BroadPath typically sees a revenue decline in Q4, Sagility’s core business remains strong in both Q3 and Q4, with Q4 historically being slightly stronger. * **Sustained H2 Momentum:** Despite mixed seasonality across businesses, Q3 and Q4 are expected to be strong overall, supported by positive demand trends and client activity. ## D. Client Cost Pressures * **Structural Demand Tailwinds:** Healthcare payers’ profitability pressures are accelerating adoption of automation in eligibility and enrollment, boosting demand for the company’s solutions. * **Regulatory & Cost-Driven Shifts:** Even absent new legislation, payers and providers are proactively investing in technology to reduce costs, reinforcing demand and offsetting offshoring risks. --- # 6. Risks & Regulatory Exposure ## A. Regulatory & Tax Exposure * **Headline Risk with Low Likelihood:** Proposed 25% U.S. excise tax on outsourcing payments poses **margin compression risk** for Sagility, though the bill has not advanced and impact would be industry-wide. * **Minimal Visa Dependency:** Over **99% of U.S. workforce** are citizens or green card holders, insulating the company from H-1B policy changes. * **Cost-Sharing Strategy:** Any tax impact would be partially passed through via client negotiations; full absorption is not expected. * **Limited Direct Impact from Trade Policy:** Tariff hikes on medical goods have affected Provider clients but resulted in **no tangible impact** on the company. ## B. Margin & AI-Driven Deflation * **Acquisition-Driven Margin Dilution:** BroadPath integration continues to dilute EBITDA margins by **120–150 bps**, offset by core business strength and cost optimization. * **Structural Revenue Pressure:** AI-led productivity is driving an estimated **5% annual revenue deflation** in the base business, already embedded in guidance. * **Cannibalization via Geographic Shifts:** Clients retaining scope but shifting work from onshore to lower-cost geographies (e.g., **$100 to $60**) create revenue erosion despite business retention. * **Seasonal Mix Impact:** Higher contribution from lower-margin BroadPath segment in Q3 exerts slight downward pressure on overall margins. ## C. Industry Dynamics & Client Demand * **Regulatory Complexity Fuels Demand:** Rising costs and stricter rules in U.S. healthcare—e.g., **Marketplace Integrity Rule**—are accelerating demand for digital transformation and efficiency solutions. * **Low Exposure to ACA Market Pressures:** Stricter enrollment rules are reducing ACA membership and premiums, but the company has **very low exposure** to this segment. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **21%+** in constant currency (↑ from 20%) · **Low to mid-teens** organic growth * **Adjusted EBITDA Margin Guidance:** **~25%** for FY26 (↑ from 24%+) · **24–25%** medium-term range ## B. Revenue Forecast * **Raised Growth Outlook:** Full-year revenue guidance increased by at least 100 bps, driven by **strong underlying demand**—particularly in healthcare—rather than competitive wallet share gains. * **Acquisition Impact:** BroadPath integration lifts combined growth outlook to **21% or more**, reflecting upward revision from prior "north of 20%" forecast. ## C. Margin Expectations * **Margin Discipline with Reinvestment:** Company maintains **24–25% EBITDA margin** as strategic baseline; excess efficiencies prioritized for growth reinvestment over sustained margin expansion. * **No Trade-Off for Growth:** Management rejects notion of sacrificing margins to accelerate growth, citing **no lost deals due to pricing** and recent margin gains achieved without compromising top-line momentum. ## D. Growth Trajectory * **Sustained Organic Expansion:** Long-term organic growth expected in **low to mid-teens** range, supported by AI-driven innovation and selective M&A for capability and market access. * **Capital Allocation:** Dividend increases anticipated over time as debt reduces, balanced with M&A flexibility and cash reserve maintenance.